News for Healthier Living

Researchers Test Imlifidase Enzyme Versus Plasma Exchange in Removing Donor-Specific Antibodies in Kidney Transplant Rejection Trial

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)--a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23-27.

October 26, 2024


October 31 2024

October 30 2024

October 29 2024

October 28 2024

October 27 2024

October 26 2024

October 25 2024

October 24 2024

October 23 2024

October 22 2024

October 21 2024

October 20 2024

October 19 2024

October 18 2024

October 17 2024